Safety and Pharmacokinetics of Antiretroviral Therapy during Pregnancy

Therapeutic Drug Monitoring

Volumn 26, Issue 2, 2004, Pages 110-115

  Rakhmanina, Natella Y ^a,b   Van Den Anker, N ^a,b   Soldin, Steven J ^a,b,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; HIV; Pregnancy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADVERSE DRUG REACTION; APGAR SCORE; AREA UNDER THE CURVE; BIRTH DEFECT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FETOTOXICITY; FETUS; FETUS DEATH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER TOXICITY; LOW APGAR SCORE; LOW BIRTH WEIGHT; MEDICAL DECISION MAKING; MENINGOMYELOCELE; PREGNANCY; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; STILLBIRTH; TERATOGENICITY; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTI-HIV AGENTS; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT;

EID: 6344237782     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200404000-00004     Document Type: Conference Paper

References (68)

1. Centers for Disease Control. National Center for HIV, STD, and TB Prevention. HIV/AIDS among US women: minority and young women at continued risk. Available at: http://www.cdc.gov/hiv/pubs/facts/women. htm, updated March 27, 2003. Accessed August 02, 2003.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS), and World Health Organization (WHO). AIDS epidemic update: December 2002. Geneva: UNAIDS/WHO 2002. Available at: http://www.who. int/hiv/pub/epidemiology/epi2002/en. Accessed August 02, 2003.
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
4. Centers for Disease Control. Update: Perinatally Acquired HIV/ AIDS-United States 1997. MMWR. 1997;46:1086-1092.
5. Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of the zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis. 1996;174:1207-1211.
6. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
7. HIV-infected pregnant women and vertical transmission in Europe since 1986. European collaborative study. AIDS. 2001;15:761-770.
8. Centers for Disease Control. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo. nih.gov/guidelines, updated July 12, 2003. Accessed August 02, 2003.
9. Perinatal HIV Guidelines Working Group. US Public Health Service Task Force recommendations on the use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available on at: http://www.aidsinfo.nih.gov/guidelines, updated June 14, 2003. Accessed August 04, 2003.
10. A guide to the clinical care of women with HIV. Anderson JR, eds. Rockville, MD: HIV/AIDS Bureau 2001. Available at: http://www.hab.hrsa. gov/publications/womencare.htm. Accessed August 04, 2003.
11. The Petra Study Team. Efficacy of three-short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomized, double-blind, placebo-controlled trial. Lancet. 2002;359:1178-1186.
12. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of HIV-1. J Infect Dis. 2003;187:725-735.
13. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet. 1999;354:795-802.
14. Ayers KM, Clive D, Tucker WE Jr, et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol. 1996;32:148-158.
15. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorogenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst. 1997;89:1602-1608.
16. Ayers KM, Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol. 1997;38:195-198.
17. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:463-467.
18. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 Jan 1989-31 Jan 2003 (issued May 2003). Wilmington, NC: Registry Coordinating Center, 2002.
19. Nightingale SL. From the Food and Drug Administration. JAMA. 1998;280:1472.
20. De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162:355.
21. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
22. Safety and toxicity of individual antiretroviral agents in pregnancy. Available at: http://www.aidsinfo.nih.gov/guidelines, updated May 23, 2003. Accessed July 14, 2003.
23. Brinkman K, Ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744.
24. Martin JL, Brown DE, Matthewa-Davis N, et al. Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38:2743-2749.
25. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
26. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who dies before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr Hum Retrovirol. 2000;15:261-268.
27. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999.
28. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med. 1999;23:100-112.
29. Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet. 1999;353:901-902.
30. Bristol-Myers Squibb Company. Healthcare Provider Important Drug Warning Letter. 2001;January:5.
31. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV-exposures worldwide, 1977-2000. MMWR. 2001;49:1153-1156.
32. Hill JB, Sheffield JS, Zeeman CG, et al. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstet Gynecol. 2001;98:909-911.
33. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189-198.
34. Food and Drug Administration. FDA Public Health Advisory: Reports of Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors for the Treatment of Human Immunodeficiency Virus (HIV). Rockville, MD: Food and Drug Administration, Public Health Service, Department of Health and Human Services, 1997.
35. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy (letter). Ann Intern Med. 1997;127:947.
36. Eastone JA, Decker CF. New-onset diabetes mellitus associated with the use of protease inhibitor (letter). Ann Intern Med. 1997;127:948.
37. Dube M. Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998;10:41-48.
38. Imas JD. Preterm birth. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies, 4th ed. New York: Churchill Livingstone, 2002:755-826.
39. Goldstein PJ, Smit R, Stevens M, et al. Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth infants. Infect Dis Obstet Gynecol. 2000;8:94-98.
40. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;24:12:F241-247.
41. Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight? The European Collaborative Study. AIDS. 1999;13:119-124.
42. European Collaborative Study and the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14:2913-2920.
43. Morris AB, Cu-Unvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr. 2000;25:306-311.
44. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life and the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:380-387.
45. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-1870.
46. Martin R, Boyer P, Hammil H, et al. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection Study Group. J Pediatr. 1997;131:851-856.
47. Leroy V, Ladner J, Nyiraziraje M, et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. Pregnancy and HIV Study Group. AIDS. 1998;12:643-650.
48. Reynolds F, Knott C. Pharmacokinetics in pregnancy and placental drug transfer. Oxf Rev Reprod Biol. 1989;11:389-449.
49. Lobstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33:328-343.
50. Gardner DK. Pharmacology and pharmacokinetics. In: Seifer DB, Samuels P, Kniss DA, eds. The Physiologic Basis of Gynecology and Obstetrics. New York: Lippincott Williams & Wilkins, 2001:75-85.
51. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol. 2001;25:120-123.
52. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immune deficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178:1327-1333.
53. th Conference on Retroviruses and Opportunistic Infections, Boston, 2003.
54. Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepratum and postpartum human immunodeficiency virus-infected women and their neonates: an AIDS Clinical Trials Group study. J Infect Dis. 1999;180:1536-1541.
55. Rodman JH, Flynn PM, Robbins B, et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. J Infect Dis. 1999;180:1844-1850.
56. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immune deficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178:368-374.
57. Mirochnick M, Siminiski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J. 2001;20:803-805.
58. Hayashi S, Beckerman K. Homma, et al. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS. 2000;14:1061-1062.
59. nd Conference on Global Strategies for the Prevention of HIV transmission from Mothers to Infants. Montreal, 1999.
60. Kosel BW, Beckerman KP, Hayashi S, et al. Pharmacokinetics of nelfinavir and indinavir in HIV-infected pregnant women. AIDS. 2003;17:1195-1199.
61. th Conference on Opportunistic Infections. Boston, 2003.
62. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002.
63. th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
64. th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001.
65. Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002;21:835-838.
66. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS. 2002;16:889-893.
67. Angel JB, Khaliq Y, Monpetit ML, et al. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy, AIDS. 2001;5:417-419.
68. Newell ML. Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS. 1998;12:831-837.